NFKB1 and acute myeloid leukemia: A recent study including primary cells of 28 AML patients showed MAPK-dependent apoptosis and NFκB-mediated myeloid differentiation of the blasts after treatment with 10 ng/mL Pam3CSK4 (TLR1/2 agonist) [16].